An abstract titled, “GLP-1 RA and Risk of Malignancy in Patients with Type 2 Diabetes,” was published in Diabetes, a publication from the American Diabetes Association, and subsequently presented by authors Faidat A. Ishola, C. William Pike, and Sun H. Kim. Dr. Pike is affiliated with Atropos Health and Dr. Ishola and Dr. Kim are affiliated with Stanford.
Short Summary:
Glucagon-like peptide 1 receptor agonists (GLP-1 RA) have been associated with both increased (Bezin 2023) and decreased risk (Wang 2023) of certain cancers in patients with type 2 diabetes (T2DM). This study investigated the risk of developing 13 obesity-associated malignancies in patients with T2DM who received GLP-1RA compared with other anti-hyperglycemic agents except insulin.
Key Conclusions:
Despite a noted increased risk for prostate cancer with GLP-1RA use, non-visible confounders limit the results. Other cancers showed no significant association with GLP-1RA use.
To learn how Atropos Health can accelerate and supplement your research with Real-World Evidence (RWE), email us: sales@atroposhealth.com